3/5
11:25 am
arqt
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]
Low
Report
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone [Yahoo! Finance]
3/5
09:28 am
arqt
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth [Yahoo! Finance]
Low
Report
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth [Yahoo! Finance]
3/5
09:00 am
arqt
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Low
Report
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
3/4
08:22 am
arqt
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen [Yahoo! Finance]
3/3
08:21 am
arqt
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]
Medium
Report
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis [Yahoo! Finance]
3/3
08:00 am
arqt
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
Medium
Report
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
3/2
08:03 am
arqt
Arcutis Biotherapeutics (ARQT) had its price target lowered by Mizuho from $37.00 to $35.00. They now have an "outperform" rating on the stock.
Medium
Report
Arcutis Biotherapeutics (ARQT) had its price target lowered by Mizuho from $37.00 to $35.00. They now have an "outperform" rating on the stock.
2/27
04:00 pm
arqt
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
Medium
Report
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
2/27
11:30 am
arqt
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? [Yahoo! Finance]
Low
Report
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? [Yahoo! Finance]
2/27
10:58 am
arqt
Arcutis Biotherapeutics (ARQT) had its price target raised by Guggenheim from $34.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Arcutis Biotherapeutics (ARQT) had its price target raised by Guggenheim from $34.00 to $35.00. They now have a "buy" rating on the stock.
2/26
12:53 pm
arqt
Arcutis Biotherapeutics (ARQT) had its price target raised by TD Cowen from $30.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
Arcutis Biotherapeutics (ARQT) had its price target raised by TD Cowen from $30.00 to $35.00. They now have a "buy" rating on the stock.
2/26
08:03 am
arqt
Arcutis Biotherapeutics (ARQT) had its price target raised by Needham & Company LLC from $31.00 to $36.00. They now have a "buy" rating on the stock.
Low
Report
Arcutis Biotherapeutics (ARQT) had its price target raised by Needham & Company LLC from $31.00 to $36.00. They now have a "buy" rating on the stock.
2/26
07:17 am
arqt
Arcutis Biotherapeutics (ARQT) had its "buy" rating reaffirmed by HC Wainwright.
Low
Report
Arcutis Biotherapeutics (ARQT) had its "buy" rating reaffirmed by HC Wainwright.
2/26
01:32 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/25
07:20 pm
arqt
Arcutis (ARQT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arcutis (ARQT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/25
06:41 pm
arqt
Arcutis Biotherapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
04:00 pm
arqt
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/24
09:15 am
arqt
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
Medium
Report
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
2/20
09:23 am
arqt
Arcutis After The Double: Hypergrowth Peaks, Compounding Remains [Seeking Alpha]
Medium
Report
Arcutis After The Double: Hypergrowth Peaks, Compounding Remains [Seeking Alpha]
2/18
07:22 pm
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy? [Yahoo! Finance]
Medium
Report
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy? [Yahoo! Finance]
2/5
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/2
08:13 am
arqt
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
Low
Report
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis [Yahoo! Finance]
2/2
08:00 am
arqt
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
Low
Report
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
1/27
08:33 am
arqt
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics announces termination of promotion agreement with Kowa [Yahoo! Finance]
1/26
11:34 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $30.00 to $31.00. They now have a "buy" rating on the stock.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) had its price target raised by analysts at Needham & Company LLC from $30.00 to $31.00. They now have a "buy" rating on the stock.